Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1993-04-19
1995-04-18
Wityshyn, Michael G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
530395, 424538, 424547, A61K 3710
Patent
active
054079128
ABSTRACT:
The present invention is directed to a stabilized keyhole limpet hemocyanin (KLH) composition in which (i) its intact non-degraded subunit is approximately 400,000 in molecular weight based on SDS-PAGE analysis; and (ii) are contained at least about 50% didecameric or higher KLH multimers, based on sedimentation-equilibrium and/or sedimentation-velocity ultracentrifugation analyses. The KLH composition is stabilized at 4.degree. C. by dissolving and storing it in an isotonic buffer preferably containing calcium and magnesium. It is critical that the KLH not have been frozen or lyophilized during its preparation or storage. The KLH composition demonstrates enhanced immunogenic activity, particularly enhanced anti-tumor activity, which is reduced if the KLH is frozen or lyophilized. The KLH composition of the present invention exhibits enhanced anti-tumor activity in a murine bladder tumor model and thereby represents a new and useful anti-tumor immunotherapeutic agent.
REFERENCES:
Senozan, N. M. et al., Hemocyanin of the giant keyhole limpet, Megathura crenulata, in: "Invertebrate Oxygen-Binding Proteins", J. Lamy et al., eds., Marcel Dekker, Inc., N.Y., pp. 703-717 (1981).
Herscowitz, H. B. et al., Immunochemical and immunogenic properties of a purified keyhole limpet haemocyanin, immunology 22:51-61 (1972).
Curtis, J. E. et al., The human secondary immune response to keyhole limpet haemocyanin, Clin. Exp. Immunol. 10:171-177 (1972).
Curtis, J. E. et al., The human primary immune response to keyhole limpet haemocyanin: Interrelatiolnships of delayed hypersensitivity, antibody response and in vitro blast transformation, Clin. Exp. Immunol. 6:473-491 (1970).
Herskovits, T. T. et al., Subunit structure and hiugher order assembly of the hemocyanins of the melongenidae family: Melongena corona (Gmelin), Busycon canaliculatum (Linne), B. carica (Gmein), B. contrarium (Conrad), and B. spiratum (Lamarck). Comp. Biochem. Physiol. [B] 94B:415-421 (1989).
Garvey, J. S., et al., High-molecular-weight hemocyanin. In: "Methods in Immunology", Addison-Wesley Publ. Co., pp. 135-139 (1977).
Herskovits, T. T., Recent aspects of the subunit organization and dissociation of hemocyanins. Comp. Biochem. Physiol. 91B:597-611 (1988).
Herskovits, T. T. et al., Higher order assemblies of molluscan hemocyanins. Comp. Bio chem. Physiol. [B] 99B:19-34 (1991).
Savel-Niemann, A. et al., Keyhole limpet hemocyanin: On the structure of a widely used immunologic tool. In: "Invertebrate Dioxygen Carriers", G. Preaux et al., eds., Leuven University Press, Leuven, pp. 351-356 (1990).
Markl, J. et al., The role of two distinct subunit types in the architecture of keyhole limpet hemocyanin (KLH). Naturwiss. 78:512-514 (1991).
Van Holde, K. E. et al., The Hemocyanins. In: "Subunits in Biological Systems", S. N. Timasheff et al., eds. Marcel Dekker, N.Y., pp. 1-53 (1971).
Ellerton, H. D. et al., Hemocyanin-A current perspective. Prog. Biophys. Mol. Biol. 41:143-248 (1983).
Silverman, D. T. et al., Epidemiology of Bladder Cancer. In: "Hematology/Oncology Clinics of North America", P. W. Kantoff et al., eds., W. B. Saunders Co., Phila. p. 1 (1992).
Itouku, K. A. et al., Superficial Bladder Cancer. In: "Hematology/Oncology Clinics of North America", P. W. Kantoff et al., eds., W. B. Saunders Co., Phila. pp. 99-116 (1992).
Morales, A. et al., Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J. Urol. 116:180-183 (1976).
Morales, A. et al., Immunotherapy for superficial bladder cancer. A developmental and clinical overview. Urol. Clin. Nor. Am. 19:549-556 (1992).
Lamm, D. L., Optimal BCG treatment of superficial bladder cancer as defined by American trials. Eur. Urol. 21 Suppl. 2:12-16 (1992).
Olsson, C. A. et al., Immunologic reduction of bladder cancer recurrence rate. J. Urol. 111:173-176 (1974).
Jurincic, C. D. et al., Immunotherapy in bladder cancer with keyhole-limpet hemocyanin: a randomized study. J. Urol. 139:723-726 (1988).
Flamm, J. et al., Recurrent superficial transitional cell carcinoma of the bladder: Adjuvant topical chemotherapy vs. immunotherapy. A prospective randomized trial. J. Uriol. 144:260-263 (1990).
Kalble, T. et al. Intravesikale rezidivprophylaze beim oberflachlichen harnblasenkarzinom mit BCG und KLH. Urologe 30:118-121 (1991).
Flamm, J. et al., Adjuvant topical chemotherapy versus immunotherapy in primary superficial transitional cell carcinoma of the bladder, Br. J. Urol. 67:70-73 (1991).
Lamm, D. L. et al., Immunotherapy of murine transitional cell carcinoma. J. Urol. 128:1104-1108 (1982).
Lamm, D. L. et al., Keyhole-limpet haemacyanin and immune ribonucleic acid immunotherapy of murine transitional cell carcinoma. Urol. Res. 9:227-230 (1981).
Lamm, D. L. et al., Immunotherapy of murine bladder cancer with keyhole limpet hemocyanin (KLH). J. Urol. 149:648-652 (1993).
Laemmli, U. K., Clevage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685 (1970).
Van Holde, K. E. et al., Boundary analysis of sedimentation-velocity experiments with monodisperse and paucidisperse solutes. Biopolym. 17:1387-1403 (1978).
Vandenbark, A. A. et al., All KLH preparations are not created equal. Cell. Immunol. 60:240-243 (1981).
Chodak, G. W. and Summerhayes, I., Detection of angiogenesis activity in malignant bladder tissue and cells. J. Urol. 132:1032 (1984).
Shapiro, A., Ratliff, T. L., Oakley, D. M. and Catalona, W. J., Reduction of bladder tumor growth in mice treated with intravesical bacillus Calmette-Guerin and its correlation with bacillus Calmette-Guerin viability and natural killer cell activity. Cancer Res. 43:1611 (1983).
Ebert Ray F.
Swerdlow Richard D.
Akzo N.V.
Blackstone William M.
Ihnen Jeffrey L.
Sayala C.
Wityshyn Michael G.
LandOfFree
Method of treating bladder cancer with a keyhole limpet hemocyan does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating bladder cancer with a keyhole limpet hemocyan, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating bladder cancer with a keyhole limpet hemocyan will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-67288